Nuclear Medicine

Nuclear medicine (also called molecular imaging) includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. Nuclear imaging is achieved by injecting small amounts of radioactive material (radiopharmaceuticals) into patients before or during their scan. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

RSS icon
Thumbnail

RSNA partners with RadSite on FDG-PET/CT biomarker pilot program

The effort is focused on outpatient imaging centers and should bring more consistency to cancer treatment and therapy.

money maze payment reimbursement

Imaging advocate applauds CMS’ decision to lift longstanding PET payment restriction

The Centers for Medicare & Medicaid Services is removing restrictions for using positron emission tomography scans outside of cancer care. 

quality

Nuclear medicine leader says patient-first imaging providers must keep close eye on quality

That includes utilizing the most up-to-date protocols and equipment, among many other things, ASNC President Randall C. Thompson said.

Thumbnail

Physicians support use of PET/CT scans in pregnant women with cancer, survey finds

Researchers say scans pose little risk to an unborn fetus but maintained doctors must weigh the benefits against potential risks.

Thumbnail

Top medical groups release new appropriate use criteria for PSMA-PET imaging

SNMMI is among the many organizations that collaborated on the updated guidance for imaging prostate cancer.

District of Columbia DC congress capitol hill

Lawmakers request records from FDA on Alzheimer’s drug approval, citing ‘apparent anomalies’

Part of their list includes info regarding the agency's move to approve Aduhelm for broader treatment indications than studied during clinical testing, a gripe similar to complaints cited by SNMMI.

District of Columbia DC congress capitol hill

Imaging advocates, bipartisan lawmakers unite to oppose ‘misguided and massive’ Medicare pay cuts

Congressmen highlighted a planned wage increase for clinical labor that will spell 20% reductions elsewhere, due to budget neutrality. 

Thumbnail

Transformative prostate cancer therapy ‘should not be accepted’ without PET imaging

Two Stanford University experts made their case for using molecular imaging to select patients for 177-Lu-PSMA-617 in a new Journal of Nuclear Medicine editorial.

Displaying 297 - 304 of 358
Design by Adaptive Theme